RT Journal Article
SR Electronic
T1 Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.15.20131706
DO 10.1101/2020.06.15.20131706
A1 Ana Marcos-Jiménez
A1 Santiago Sánchez-Alonso
A1 Ana Alcaraz-Serna
A1 Laura Esparcia
A1 Celia López-Sanz
A1 Miguel Sampedro-Núñez
A1 Tamara Mateu-Albero
A1 Ildefonso Sánchez-Cerrillo
A1 Pedro Martínez-Fleta
A1 Ligia Gabrie
A1 Luciana del Campo Guerola
A1 Margarita López-Trascasa
A1 Enrique Martín-Gayo
A1 María Calzada
A1 Santos Castañeda
A1 Hortensia de la Fuente
A1 Isidoro González-Álvaro
A1 Francisco Sánchez-Madrid
A1 Cecilia Muñoz-Calleja
A1 Arantzazu Alfranca
YR 2020
UL http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131706.abstract
AB Background SARS-CoV-2 infection causes an abrupt response by the host immune system, which is largely responsible for the pathogenesis and outcome of COVID-19. We aimed to investigate which specific responses from either cellular or humoral immunity associate to severity and progression of COVID-19.Methods A cohort of 276 patients classified in mild, moderate and severe, was studied. Peripheral blood lymphocyte subpopulations were quantified by flow cytometry, and immunoglobulins and complement proteins by nephelometry.Results At admission, dramatic lymphopenia of T, B and NK cells associated to severity. However, only the proportion of B cells increased, while T and NK cells appeared unaffected. Accordingly, the number of plasma cells and circulating follicular helper T cells (cTfh) increased, but levels of IgM, IgA and IgG were unaffected. When degrees of severity were considered, IgG was lower in severe patients, suggesting an IgG consumption by complement activation or antibody-dependent cellular cytotoxicity (ADCC). Activated CD56-CD16+ NK-cells, which mediate ADCC, were increased. Regarding complement, C3 and C4 protein levels were higher in mild and moderate, but not in severe patients, compared to healthy donors. Moreover, IgG and C4 decreased from day 0 to day 10 in patients who were hospitalized for more than two weeks, but not in patients who were discharged earlier.Conclusion Our study provides important clues to understand the immune response observed in COVID-19 patients, which is probably related to viral clearance, but also underlies its pathogenesis and severity. This study associates for the first time COVID-19 severity with an imbalanced humoral immune response characterized by excessive consumption of IgG and C4, identifying new targets for therapeutic intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by grants SAF2017-82886-R to FS-M from the Ministerio de Economia y Competitividad, and from La Caixa Banking Foundation (HR17-00016) to FS-M. Grant PI018/01163 to CMC and grant PI19/00549 to AA were funded by Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo, Spain. SAF2017-82886-R, PI018/01163 and PI19/00549 grants were also co-funded by European Regional Development Fund, ERDF/FEDER.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the local Research Ethics Committee (register number 4070) and it was carried out following the ethical principles established in the Declaration of Helsinki. All included patients were informed about the study and gave an oral informed consent because of COVID-19 emergency as proposed by AEMPS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon reasonable request to the corresponding author